

FOR IMMEDIATE RELEASE

December 23, 2020

STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF

Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison

Phone: (919) 903-2057

Email: kevin.scorsone@ncoda.org

www.ncoda.org

MOST FAVORED NATION: TEMPORARY RESTRAINING ORDER ISSUED

NCODA has been in opposition of the *Most Favored Nation* (MFN) model for Medicare patients since it was announced late last month. The model would negatively affect patient access to Part B drugs – the anti-cancer (oral and infused) treatments that are administered in oncology practices.

Today, it was announced that US District Court Judge Catherine Blake (Maryland) issued a two-week temporary restraining order (TRO) which delays the implementation of the MFN model. The two-week reprieve allows the court time to consider implementing a preliminary injunction against the MFN model.

This mandatory 7-year payment model would establish reimbursement to providers based on an MFN price for the 50 highest cost Part B drugs. The MFN price would be phased in to replace the current ASP reimbursement model and would be based on international pricing from other similar countries.

This model would create a potentially insurmountable challenge for oncology practices, and it would hurt the people who matter most – the patients. NCODA continues to oppose this model and will monitor and update our membership as progress is made on this decision.



Michael Reff, RPh, MBA

Founder & Executive Director | NCODA, Inc.



PASSION FOR PATIENTS
ncoda.org

P.O. Box 468 Cazenovia NY 13035
501(c)(3) organization